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Background.The beneficial effects of testosterone treatment (TT) are debated.Methods. Double-blinded, placebo-controlled study
of sixmonths TT (gel) in 54men aged 60–78 with bioavailable testosterone (BioT)<7.3 nmol/L andwaist>94 cm randomized to TT
(50–100mg/day, 𝑛 = 20), placebo (𝑛 = 18), or strength training (ST) (𝑛 = 16) for 24 weeks.Moreover, the ST groupwas randomized
to TT (𝑛 = 7) or placebo (𝑛 = 9) after 12 weeks. Outcomes. Chemokines (MIF, MCP-1, and MIP-1𝛼) and lean body mass (LBM),
total, central, extremity, visceral, and subcutaneous (SAT) fat mass established by DXA andMRI. Results. From 0 to 24 weeks, MIF
and SAT decreased during ST + placebo versus placebo, whereas BioT and LBM were unchanged. TT decreased fat mass (total,
central, extremity, and SAT) and increased BioT and LBM versus placebo. MIF levels increased during TT versus ST + placebo.
ST + TT decreased fat mass (total, central, and extremity) and increased BioT and LBM versus placebo. From 12 to 24 weeks,
MCP-1 levels increased during TT versus placebo and MCP-1 levels decreased during ST + placebo versus placebo. Conclusion.
ST + placebo was associated with decreased MIF levels suggesting decreased inflammatory activity. TT may be associated with
increased inflammatory activity. This trial is registered with ClinicalTrials.gov NCT00700024.
1. Introduction
Testosterone replacement therapy is indicated in severe
hypogonadism, whereas the indication for testosterone ther-
apy (TT) in aging hypogonadal men without hypothalamic,
pituitary, or testicular disease is debated [1, 2]. In partic-
ular, the effects of TT on metabolic and cardiovascular
outcomes are undetermined [3]. Recently, we reported that
TT increased lean body mass (LBM) and lipid oxidation [1],
whereas lower extremity fat mass (LEFM) and abdominal
subcutaneous adipose tissue (SAT) decreased, but visceral
adipose tissue (VAT) was unchanged [4]. In addition to these
testosterone-induced changes in body composition and lipid
metabolism, we observed decreased levels of high density
lipoprotein, adiponectin, and osteoprotegerin [5], whereas
the cardiovascular risk markers, LDL, c-reactive protein, and
insulin sensitivity measured by clamp were unchanged [1, 4].
Recent meta-analyses found no effect of TT on cardiovascu-
lar outcomes, but the duration of the included studies was
limited and cardiovascular outcomes were not reported in all
trials [6]. The overall interpretation of the combined effects
of TT on metabolic and cardiovascular risk factors remains
undetermined, and additional studies are needed.
Adiposity is a major component of the metabolic syn-
drome and an independent risk factor for the develop-
ment of type 2 diabetes and cardiovascular disease [7].
Human adipose tissue produces and releases a number of
bioactive proteins, collectively referred to as adipokines [8].
Adipokines are primarily secreted by adipose tissue-resident
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macrophages [9]. In obesity, the number of adipose tissue-
resident macrophages is increased in both SAT and VAT [10,
11], and circulating mononuclear cells are in a more inflam-
matory state [12]. Chemokines are an important subgroup
of adipokines, which activate (chemoattract) mononuclear
cells during the process of inflammation. Increasing adiposity
is associated with influx of monocytes to the AT with con-
comitant differentiation of AT-resident macrophages from a
primarily anti-inflammatory to a proinflammatory state [10].
Interestingly, the influx of monocytes may be orchestrated
by several chemokines. Monocyte chemoattractant protein-1
(MCP-1) and migration inhibitor factor (MIF) are positively
associated with obesity [13–15]; these chemokines have the
ability to induce insulin resistance [16] and are predictors
for type 2 diabetes [17]. Obesity is inversely associated with
testosterone levels [18], but the effect of TT on chemokine
levels remains to be established.
Aging men with low normal testosterone levels are often
characterized by decreased LBM, decreased muscle strength,
and relative inactivity [19]. Physical exercise is associatedwith
decreased chemokine levels [13, 31]. We are not aware of pre-
vious studies evaluating the effect of combined testosterone
and strength exercise on chemokine levels in ageing men.
In the present study, we investigated the effects of TT on
chemokine levels in aging men with low normal testosterone
levels [18] and increased waist circumference. We hypoth-
esized that decreased SAT during TT could be associated
with decreased chemokine levels. We furthermore examined
if strength exercise with and without TT was associated with
decreased chemokine levels.
2. Methods
The study was a single center, randomized, placebo-con-
trolled, six-month study to assess the effect of testosterone gel
and strength training (ST) on body composition, components
of themetabolic syndrome, and quality of life inmenwith low
normal bioavailable testosterone (BioT) levels and increased
body fat. The inclusion criteria for participation in the study
were age 60–78 years, BioT <7.3 nmol/L, and waist cir-
cumference >94 cm. The exclusion criteria were hematocrit
>50%, prostate cancer or a prostate specific antigen >3 ng/dL,
previous or ongoingmalignant disease, severe ischemic heart
or respiratory disease, disability, diabetes mellitus, alcohol or
drug abuse, abnormal routine blood samples (TSH, ionized
calcium, hemoglobin, and liver and kidney functions), and
treatment with 5𝛼 reductase inhibitors, morphine, or oral
glucocorticoid steroids.
The sample size of the study was determined by the effect
of TT on LBM and has been described previously [1]. LBM
was chosen as the primary study outcome based on a meta-
analysis on testosterone therapy in ageing men by Isidori et
al. [20]. Chemokine levels were secondary study outcomes.
Subjects were randomly assigned to receive testosterone
(TT, 𝑛 = 20), placebo (𝑛 = 18), or engage in strength
training (𝑛 = 16) as previously described [1]. After 12 weeks,
the ST group was randomized into two groups receiving
testosterone or placebo (ST + TT, 𝑛 = 7, and ST + placebo,
Month
0 3 6
Training + testosterone
n = 7
Training + placebo
n = 9
Randomization
n = 54
Training
n = 16
Placebo
n = 18
Testim
n = 20
Figure 1: Study design.
𝑛 = 9) (Figure 1). Treatment with testosterone and placebo
was double blinded. Randomization numbers were assigned
to the participants in order of enrollment into the study.
The study was approved by the local Ethics Committee and
declared in http://www.clinicaltrials.gov/ (NCT00700024).
All participants gave written informed consent. Exclusion
criteria were hematocrit >50%, prostate cancer or a prostate
specific antigen (PSA) >3 ng/dL, previous or ongoing malig-
nant disease, severe ischemic heart or respiratory disease,
disability, diabetes mellitus, alcohol or drug abuse, abnormal
routine blood samples (TSH, ionized calcium, hemoglobin,
and liver and kidney functions), and treatmentwith 5𝛼 reduc-
tase inhibitors, morphine, or oral glucocorticoid steroids.
Four patients had previous apoplexia cerebri, and three
patients had ischemic heart disease. None of the study
participants were restricted during daily living activities.
A total of 42% of participants were on antihypertensive
drugs, 29% were on cholesterol-lowering drugs, 10% were
on inhalation steroids, 6% were on antidepressants, and
4% were treated for enlarged prostate. The distribution of
concomitant medication in the treatment arms was equal.
No cholesterol-lowering drugs or other medications were
introduced during the study. Participants received 5–10 g
gel/50–100mg testosterone (Testim, Ipsen, France) or 5–10 g
gel/placebo. The randomization list, medicine labeling, and
randomization and code break envelopes were generated by
Ipsen Scandinavia (Kista, Sweden) to ensure double blinding.
Compliance was monitored by participant self-reporting at
each visit.The study outcomes were evaluated at baseline and
after three and six months’ intervention.
2.1. Training Protocol. The training protocol has been
described recently [21]. In brief, participants performed 5min
bicycling for warm up (approximately 100W) followed by
a progressive heavy strength training program including
exercises for the entire body and gradually increased training
loads [21]. All training sessions were supervised, and patients
and supervisors were blinded for placebo/testosterone treat-
ment. All subjects participated in minimum 2 out of 3
weekly training sessions (mean training adherence 75 ± 8%).
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Subjects were advised to refrain from self-initiated resistance
exercise training and intense endurance training but were
allowed to continue on other habitual activities throughout
the study. All subjects received 0.2 liter of skimmed chocolate
milk (containing 7 g protein, 20 g carbohydrate, and 1 g fat)
after each strength training session, but in addition, subjects
were informed not to change their diet.
2.2. Biochemical Analyses
2.2.1. Chemokines. Plasma levels of the investigated chem-
okines were assessed using a specific human enzyme-linked
immunosorbent assay (ELISA) method (DuoSet, R&D Sys-
tems Europe Ltd., UK). MCP-1, macrophage inflammatory
protein- (MIP-) 1𝛼, andMIF assays had intra-assay coefficient
of variation (CV) of 8.1% (𝑛 = 12), 7.1% (𝑛 = 12), and 4.6%
(𝑛 = 12), respectively. The samples used for the chemokine
analyses had not previously been thawed.
2.2.2. Testosterone and SHBG. Testosterone was measured
after an overnight fast between 8 and 9 AM. Serum
total testosterone was measured by liquid chromatogra-
phy tandem mass spectrometry after ether extraction. For
testosterone measurements, the intra-assay coefficient of
variation was 10% for total testosterone >0.2 nmol/L and
30% in the range between 0.1 and 0.2 nmol/L. SHBG
was measured by autoDELFIA assay, and BioT was calcu-
lated according to the formulas of Vermeulen et al. [22],
http://www.issam.ch/freetesto.htm. During calculations, we
used the assumption that albumin concentration in partic-
ipants was 4.3 g/L. A single measurement of testosterone
was performed to determine eligibility. BioT levels were all
below 7.3 nmol/L at reevaluation after three weeks on placebo
treatment (𝑛 = 18). The normal range and 95% confidence
interval for BioT were 7.3 nmol/L (7.0–7.5 nmol/L) [18].
2.3. Body Composition Measures
2.3.1. Dual X-Ray Absorptiometry (DXA). TFM, central fat
mass (CFM), lower extremity fat mass (LEFM), and LBM
were measured by DXA using a Hologic Discovery device
(Waltham, MA, USA). The CV was 0.8% for TFM and 0.6%
for LBM, respectively.
2.3.2. Magnetic Resonance Imaging. Magnetic resonance
imaging was performed as previously reported [4]. In brief,
a 3.0 Tesla High field MR Unit was used (Philips Achieva,
Phillips Healthcare, Best, The Netherlands). One abdominal
slice (10mm thick, intervertebral space of L4/L5, perpendic-
ular to subcutaneous fat) was recorded. Computer software
was used to trace the different compartments of fat on
the abdomen and for assessment of the areas of SAT and
VAT. The thigh fat area was determined on one femoral
slice (15 cm from the major trochanter and perpendicular
to subcutaneous fat) using a T1-weighted gradient-echo
sequence (repetition time 400ms, echo time 18ms, acquisi-
tionmatrix 376 × 335, field of view 230 × 230mm). Computer
software was used to trace fat and muscle compartments on
the thigh to assess subcutaneous and intramuscular fat and
thigh muscle area [23]. Due to various reasons (claustropho-
bia, did not attend, and did not want examination), complete
MRI data were only available for 54 patients. The number
of patients not attending first MRI was placebo: 2, TT: 1, ST
+ placebo: 1, and ST + TT: 2. The number of patients not
attending the MRI at study termination was placebo: 2, TT:
1, ST + placebo: 2, and ST + TT: 1. Patients without MRI were
included in the data analyses that did not include MRI data.
2.4. Statistical Analysis. Pretreatment differences between
patients in the testosterone and placebo group were tested
using the Mann-Whitney U tests. The effect of placebo, TT,
ST + placebo, and ST + TT was analyzed by comparing
delta (Δ) values of hormonal and metabolic variables using
the Mann-Whitney U tests. Δ-values were calculated as post
treatment level minus pretreatment level of each analyzed
variable. In this way, Δ-values were positive if the measured
variable increased during intervention. Δchemokine levels
were correlated with Δ-values of hormonal and metabolic
variables using the Spearman nonparametric correlation
tests.
All statistics were performed using SPSS 17.0 (SPSS
Inc., Chicago, USA) for calculations and 𝑃 values < 0.05.
were considered significant. Data are given as median and
interquartile range.
3. Results
3.1. Study Population (𝑛 = 54). Baseline data are shown
in Table 1. There were no significant differences at baseline
regarding age, chemokine levels, and body composition.
Baseline data on testosterone and body composition in
the testosterone and placebo groups have been presented
previously [1, 4].
3.2. Intervention. Changes in chemokines, BioT, and body
composition during 3 and 6 months’ intervention are shown
in Table 2 (effects of TT and ST on BioT and body compo-
sition have recently been discussed) [4, 21]. MIP-1𝛼 levels
and VAT were unchanged during all interventions at 3 and
6 months, VAT data not shown.
TT alone had no significant effects on muscle strength,
whereas ST significantly increased muscle strength inde-
pendent of the addition of testosterone (data not shown,
discussed in [21]).
3.3. Six-Month Effects (6–0). Circulating MIF levels de-
creased during ST + placebo and were significantly different
from changes in MIF during placebo and changes during TT,
but not from changes in MIF during ST + TT (Table 2).
TT increased BioT and LBM versus placebo, and fat mass
(TFM, CFM, LEFM, and SAT) decreased.
ST + placebo decreased fat mass (TFM, LEFM, and SAT)
versus placebo without significantly affecting BioT and LBM.
ST+TTwas followed by similar BioT andLBMcompared
to TT alone. The beneficial effects of ST + TT on fat mass
measures were comparable to ST + placebo.
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Table 1: Baseline data.
Placebo
(𝑛 = 18)
TT
(𝑛 = 20)
ST
(𝑛 = 16)
Age (years) 67 (65–70) 68 (62–72) 68 (62–73)
MIF (pg/mL) 203 (128–378) 182 (117–453) 259(199–498)
MCP-1 (pg/mL) 71 (59–86) 72 (63–105) 87 (64–101)
MIP-1𝛼
(pg/mL) 27 (13–1981) 17 (9–1257) 29 (11–1764)
BioT (nmol/L) 4.4 (3.3–6.0) 5.1 (4.3–6.1) 5.3 (2.2–6.2)
LBM (kg) 64.7(58.5–73.3)
64.6
(57.2–71.3)
65.4
(60.2–72.0)
Waist (cm) 105 (98–118) 107 (103–115) 107 (104–115)
Fat mass (kg) 23.9(18.2–33.1)
24.3
(21.4–31.8)
25.2
(22.5–28.7)
Central fat
mass (kg) 13.1 (9.0–18.4)
14.0
(12.5–18.2)
14.7
(12.3–17.4)
SAT 24.2(21.5–34.9)
29.3
(24.5–40.7)
27.9
(24.6–33.1)
VAT 15.6(11.5–20.0)
15.1
(12.4–19.3)
16.5
(12.3–19.3)
Data presented as median (interquartile range).
Baseline data from the subgroups ST + placebo and ST + TT can be seen in
Table 2.
No significant differences, Mann-Whitney test between groups.
BioT: bioavailable testosterone.
LBM: lean body mass.
SAT: subcutaneous adipose tissue.
VAT: visceral adipose tissue.
3.4. Three-Month Effects (3–0). Chemokine levels were
unchanged during the first three months of intervention
(Table 2).
3.5. Three-Month Effects (6–3). ST + placebo versus placebo
and versus ST + TT was followed by decreased MCP-1 levels
(Table 2).
3.6. Bivariate Associations between ΔChemokines and ΔBody
Composition Measures ST + TT (6–0). ΔMIF was signifi-
cantly associated with Δfat (r = −0.83, 𝑃 < 0.05) and ΔLEfat
(r = −0.86, 𝑃 < 0.05). ΔMIP was significantly associated with
Δfat (𝑟 = −0.93, 𝑃 < 0.001), ΔCFM (𝑟 = −0.75, 𝑃 < 0.05),
and ΔLEfat (𝑟 = −0.96, 𝑃 < 0.001).
3.7. TT and ST + Placebo (6–0). No significant associations
were found between Δchemokine levels and Δfat mass mea-
sures during TT or during ST + placebo.
4. Discussion
In the present study,MIF levels increased during TT, whereas
ST + placebo was associated with decreased MIF and MCP-
1 levels in ageing men with low normal BioT and increased
waist circumference. Our findings suggest opposing effects of
TT and ST on inflammatory status.
Given the on-going debate on testosterone therapy in
aging hypogonadal men without pituitary or testicular dis-
ease, it is important to clarify possible favorable or unfa-
vorable effects of testosterone therapy [24]. Our findings of
positive associations between testosterone and chemokine
levels support previous observations of higher circulating
MIF in males compared to females [17, 25] and findings
from cross-sectional studies [25]. Patients with polycystic
ovary syndrome and hyperandrogenemia showed a BMI and
SHBG independent correlation between chemokine levels
and testosterone, further supporting that high testosterone
levelsmay increase inflammationmarkers [26]. In the present
study,ΔBioT andΔchemokine levels were not associated, and
these data do not support a direct effect of testosterone on
inflammatory status. Instead, the effects of TT on chemokine
secretion could be indirectly affected by other (inflammatory)
pathways or by factors such as fat mass or LBM as discussed
below.
We are not aware of previous studies that evaluated the
long-term effect of randomized TT on chemokine levels in
ageingmale study populations. Six-monthDHEAS treatment
in women with adrenal insufficiency did not affect MCP-
1 levels despite increased LBM [27], but fat distribution
was unchanged and MIF data were not available in the
study. Interestingly, animal studies showed that rats express
MIF in Leydig cells, but whether MIF affects human repro-
duction is undetermined [25, 28]. Exogenous testosterone
could increase MIF levels through a decreased testicular
LH stimulation, but future studies are needed to test this
hypothesis. The present data along with previous studies
therefore support that increased testosterone levels are asso-
ciated with increased chemokine levels. Increased circulating
levels of MCP-1 and MIF are positively associated with the
development of various metabolic diseases such as type 2
diabetes, atherosclerosis, and cardiovascular disease [29, 30].
The impact of increased chemokine levels during testosterone
treatment on long-term cardiovascular risk awaits long-term
studies.
In the present study, ST was associated with reducedMIF
andMCP-1 levels suggesting decreased inflammatory activity.
These findings support previous reports in which lifestyle
intervention with diet and/or increased physical activity
decreased circulating chemokine levels, reduced infiltration
of macrophages into the AT, and improved whole-body
inflammation [31]. We found that MCP-1 levels decreased
during the last three months of the intervention period.
This could suggest that longer time of exercise is needed to
improve inflammatory status perhaps mediated by improved
body composition during physical exercise. Chemokine
secretion is higher in VAT than in SAT [11, 32] and inflamma-
tion is unchanged when the SAT depot is selectively reduced
by abdominal liposuction [33]. Our study supports these
findings as SAT decreased along with adiponectin during
TT [4]. In the present study, however, VAT was unchanged
during TT and ST, and the highest decrease in SAT was
observed during TT. We found that ΔMIF and ΔMIP were
strongly inversely associated with ΔLEFM supporting that
a “pear-shape” is associated with decreased inflammatory
activity [34, 35] as well as higher adiponectin levels [35].
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Table 2: Clinical and biochemical characteristics in patients during testosterone, placebo, and strength training.
Placebo
𝑛 = 18
TT
𝑛 = 20
ST
ST + placebo
𝑛 = 9
ST
ST + TT
𝑛 = 7
MIF (pg/mL)
𝑡 = 0 (3–0) 203 (128–378) 182 (117–453) 266 (118–660) 253 (228–394)
𝑡 = 3 (6–3) 205 (136–411) 282 (183–582) 207 (119–704) 277 (239–376)
𝑡 = 6 (6–0)∗ 227 (141–649) 412 (170–777) 129 (101–471)¤# 235 (169–301)
MCP-1 (pg/mL)
𝑡 = 0 (3–0) 71 (59–85) 72 (63–105) 98 (62–109) 85 (59–87)
𝑡 = 3 (6–3)∗ 74 (56–101) 84 (67–107)# 93 (70–117)# 76 (58–93)¤§
𝑡 = 6 (6–0) 82 (62–101) 80 (64–100) 72 (58–93) 79 (59–105)
MIP-1𝛼 (pg/mL)
𝑡 = 0 (3–0) 27 (13–1981) 17 (8–1257) 13 (8–827) 200 (18–2884)
𝑡 = 3 (6–3) 26 (13–1855) 17 (11–1318) 14 (9–798) 263 (18–2390)
𝑡 = 6 (6–0) 31 (13–1800) 16 (10–1059) 13 (8–856) 347 (18–2152)
BioT (nmol/L)
𝑡 = 0 (3–0)∗ 4.4 (3.3–6.0) 5.1 (4.3–6.1)## 5.1 (5.0–6.2)¤ 5.7 (4.8–6.2)##§§
𝑡 = 3 (6–3) 4.3 (3.3–4.8) 8.1 (5.6–12.3) 4.5 (4.2–5.0) 4.5 (4.1–5.1)
𝑡 = 6 (6–0)∗∗ 3.9 (3.4–4.8) 9.7 (6.5–13.8)# 4.3 (3.7–4.4)¤ 12.8 (7.3–16.3)##§
LBM (kg)
𝑡 = 0 (3–0)∗∗ 64.7 (58.5–73.2) 64.7 (57.2–71.2)# 63.2 (59.8–68.7) 70.9 (65.1–78.2)##§
𝑡 = 3 (6–3) 65.2 (58.9–73.3) 66.1 (59.9–72.2) 63.2 (57.5–68.9) 73.1 (63.3–78.2)
𝑡 = 6 (6–0)∗ 64.3 (58.8–74.7) 65.8 (59.3–72.6)# 63.8 (5.9–6.9) 75.4 (66.0–78.7)#
Fat mass (kg)
𝑡 = 0 (3–0) 23.9 (18.2–33.1) 24.4 (21.4–31.8) 25.0 (20.9–28.9) 25.4 (24.0–27.1)
𝑡 = 3 (6–3) 24.3 (18.0–32.1) 23.8 (21.4–31.3) 25.9 (21.5–28.0) 25.9 (22.9–26.3)
𝑡 = 6 (6–0)∗ 25.1 (19.2–31.3) 23.0 (20.3–30.2)# 24.2 (21.5–27.8)# 24.7 (21.5–25.9)#
CFM (kg)
𝑡 = 0 (3–0) 13.1 (9.0–18.4) 14.0 (12.5–18.2) 13.9 (11.8–17.6) 15.0 (13.7–16.9)
𝑡 = 3 (6–3) 13.1 (8.5–18.4) 13.6 (12.2–18.2) 14.5 (12.2–16.5) 14.6 (13.6–15.7)
𝑡 = 6 (6–0)∗ 13.5 (9.2–17.6) 13.9 (11.2–17.4)# 12.4 (12.1–15.6) 13.5 (13.1–15.9)#
LEfat (kg)
𝑡 = 0 (3–0) 6.9 (5.6–9.5) 6.5 (5.6–7.9) 7.2 (5.7–8.6) 7.4 (6.4–8.1)
𝑡 = 3 (6–3) 7.2 (5.3–9.8) 6.4 (5.5–8.2) 7.2 (5.7–8.4) 6.8 (6.6–7.5)
𝑡 = 6 (6–0)∗ 7.2 (5.8–9.7) 6.1 (5.2–8.0)# 6.8 (5.3–8.2)# 6.6 (6.5–7.2)#
SAT
𝑡 = 0 (3–0) 24.2 (21.5–34.9) 29.2 (24.5–40.7) 29.6 (24.9–39.7) 27.9 (23.2–28.3)
𝑡 = 3 (6–3)∗ 23.7 (20.8–35.3) 29.7 (24.2–40.1)## 30.3 (25.2–39.9)# 26.7 (23.4–28.7)¤§
𝑡 = 6 (6–0)∗∗ 25.7 (20.2–36.5) 25.6 (21.7–37.2)# 29.7 (24.0–37.4)# 26.6 (23.5–31.1)¤§
Data presented as median (interquartile range).
Kruskall-Wallis tests followed by Mann-Whitney test performed on delta values.
∗
𝑃 < 0.05 between groups, ∗∗𝑃 < 0.001 between groups (delta values).
#
𝑃 < 0.05 versus placebo, ##𝑃 < 0.001 versus placebo.
¤
𝑃 < 0.05 versus testosterone.
§
𝑃 < 0.05 versus training + placebo.
ST: strength training.
TT: testosterone treatment.
LBM: lean body mass.
SAT: subcutaneous adipose tissue.
Visceral adipose tissue was unchanged during all interventions, and these results are omitted from the table.
The strong inverse association between ΔMIF and ΔMIP and
central and total fat mass during ST + TT treatment was an
unexpected finding in the present study. ΔVAT and ΔSAT
were unassociated with Δchemokine levels suggesting that
changed fat mass was not the only predictor of chemokine
levels.
In the present study, resistance training and not aerobic
training was included in the intervention. A recent study in
patients with type 2 diabetes found that aerobic training was
associated with similar weight loss but had more beneficial
effects on inflammatory markers than ST [36]. Future studies
are needed to evaluate possible effects of various exercise
interventions on inflammatory status in men during TT.
Change in LBM was our main study outcome [20]. We
found that LBM was unaffected by ST alone, whereas TT
alone or in combination with ST significantly increased LBM
with no additional effect of the addition of testosterone. Our
findings of increased LBM independent of muscle strength
are in agreementwith previous studies and have recently been
discussed [21]. We found no significant association between
changes in chemokine levels and changes in LBM, suggesting
that muscle tissue is not the main regulator of chemokine
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secretion. Indeed, muscle tissue expresses and releases very
low levels of chemokines even in relation to exercise [31].
In conclusion, the findings of the present study support
that TT and ST have similar and positive effects on fat mass;
however, ST is superior to TT regarding chemokine levels,
inflammatory status, and body strength. Further studies on
cardiovascular end points are needed to determine the long-
term effects of TT alone and in combination with lifestyle
intervention in ageing men with low normal BioT.
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